Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373135 | 1.00 | CD274 (0.51) | CD274EPHX2ALDH1A1HTR1AMAOA | |
| SCHEMBL11989202 | 0.82 | CFTR (0.42) | TSHR | |
| SCHEMBL2372591 | 0.81 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2372492 | 0.79 | CFTR (0.41) | — | |
| SCHEMBL2382610 | 0.78 | THRB (0.51) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3274505 | 0.77 | CD274 (0.51) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL2372053 | 0.76 | P2RX7 (0.51) | TSHR | |
| SCHEMBL2383186 | 0.75 | POLB (0.56) | ALDH1A1TSHRKMT2A | |
| SCHEMBL14784270 | 0.74 | CFTR (0.42) | ALDH1A1 | |
| SCHEMBL2372384 | 0.71 | HPGDS (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |